Agilent Technologies, Inc. $A Shares Bought by BSW Wealth Partners

BSW Wealth Partners grew its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 8.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,316 shares of the medical research company’s stock after purchasing an additional 413 shares during the period. BSW Wealth Partners’ holdings in Agilent Technologies were worth $627,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agilent Technologies by 13.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock valued at $4,279,000 after buying an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Agilent Technologies by 8.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock valued at $3,606,000 after purchasing an additional 2,371 shares in the last quarter. Alps Advisors Inc. raised its holdings in Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock worth $1,563,000 after purchasing an additional 3,040 shares during the last quarter. D.A. Davidson & CO. boosted its position in Agilent Technologies by 30.4% during the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock worth $1,108,000 after purchasing an additional 2,207 shares in the last quarter. Finally, LGT Capital Partners LTD. grew its holdings in Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock valued at $89,870,000 after purchasing an additional 54,302 shares during the last quarter.

Agilent Technologies Stock Performance

NYSE:A opened at $138.75 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The firm has a market cap of $39.34 billion, a PE ratio of 32.57, a P/E/G ratio of 4.19 and a beta of 1.26. The firm has a 50 day simple moving average of $122.00 and a 200-day simple moving average of $116.17. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. Agilent Technologies’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.24%.

Analysts Set New Price Targets

A has been the topic of several recent research reports. Wall Street Zen lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Barclays reaffirmed an “equal weight” rating and issued a $125.00 price target on shares of Agilent Technologies in a report on Friday, August 29th. Evercore ISI lowered their price target on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating on the stock in a research report on Thursday, August 28th. Robert W. Baird lifted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Finally, Wells Fargo & Company increased their target price on Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, September 15th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.08.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.